| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2352 |
| Trial ID | NCT04381741 |
| Disease | Diffuse Large B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Co-treatment | Tislelizumab |
| Generation | 4th |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma |
| Year | 2020 |
| Country | China |
| Company sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Other ID(s) | IR2020001132 |
| Cohort 1 | |||||||||
|
|||||||||